Shukra Pharmaceuticals (524632) Q4 11/12 earnings summary

Executive summary

• FY12 revenue from operations was ₹66.33m versus ₹98.63m; net profit rose to ₹9.54m, supported by a ₹25.39m extraordinary gain from bank-loan settlement.

• Operations were described as being in restructuring, with turnover improvement a stated priority.

Financial highlights

• Revenue from operations declined to ₹66.33m from ₹98.63m; total revenue was ₹66.49m versus ₹99.93m.

• Profit before extraordinary items and tax was a loss of ₹1.70m versus profit of ₹7.11m; PBT was ₹20.50m after extraordinary income of ₹25.39m.

• Net profit was ₹9.54m versus ₹6.81m; no dividend was recommended in view of losses carried forward.

Outlook and guidance

• Plans included pursuing ISO 9000 certification and expanding international reach; a sophisticated injectable plant was described as established.

• Turnover improvement and financial strengthening through profitability were stated priorities amid an ongoing restructuring process.